Skip to main content

Table 3 Inter-patient heterogeneity of apoptotic and DNA repair responses in relation to clinical covariates

From: Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC

Clinical parameters

%FLICA

p-value

%FLICACD4+

p-value

%FLICACD8+

p-value

ɣH2AX foci 1 Gy 0.5 h

p-value

ɣH2AX foci 4 Gy 24 h

p-value

Age

0.3

 

0.008

 

0.1

 

1.0

 

1.0

  ≤ 55 y

41.0 (34.40, 45.35)

 

29.2 (24.95, 38.40)

 

39.2 (31.15, 51.40)

 

11.7 (11.09, 13.18)

 

6.2 (5.17, 7.09)

 

  > 55 y

38.6 (31.23, 44.10)

 

24.8 (18.80, 33.00)

 

35.8 (26.70, 47.30)

 

11.8 (11.08, 12.70)

 

6.2 (5.45, 7.08)

 

Gender

0.7

 

0.6

 

0.3

 

0.9

 

0.5

 Male

40.5 (31.88, 45.93)

 

27.9 (21.38, 34.95)

 

37.9 (30.93, 49.30)

 

11.7 (11.13, 12.79)

 

6.2 (5.46, 7.08)

 

 Female

36.1 (33.70, 42.45)

 

28.0 (18.90, 34.70)

 

33.9 (26.80, 44.80)

 

11.8 (11.02, 13.03)

 

6.1 (4.58, 7.08)

 

T-Category

0.1

 

0.2

 

1.0

 

0.3

 

0.8

 T0–2

41.6 (33.70, 46.90)

 

29.0 (21.30, 37.10)

 

38.4 (30.00, 49.70)

 

11.8 (10.65, 12.39)

 

6.1 (5.28, 7.19)

 

 T3–4

35.9 (31.07, 42.45)

 

26.8 (20.30, 33.05)

 

36.5 (30.50, 48.65)

 

11.7 (11.17, 13.26)

 

6.2 (5.21, 7.06)

 

N-Category

0.8

 

0.6

 

0.7

 

0.2

 

0.6

 N0–1

38.9 (31.07, 49.45)

 

25.6 (19.75, 33.00)

 

38.4 (26.70, 47.30)

 

11.4 (10.87, 11.80)

 

5.7 (5.18, 7.33)

 

 N2–3

39.9 (33.55, 44.85)

 

28.0 (21.30, 35.40)

 

36.8 (30.70, 49.70)

 

11.8 (11.09, 13.03)

 

6.2 (5.27, 7.08)

 

TNM stage

0.7

 

0.6

 

0.6

 

1.0

 

0.3

 III

39.9 (33.47, 44.85)

 

28.0 (21.00, 34.70)

 

36.8 (30.70, 47.10)

 

11.8 (11.02, 12.89)

 

6.1 (5.21, 7.00)

 

 IVA/B

39.3 (32.75, 46.63)

 

28.0 (21.27, 35.30)

 

36.8 (29.13, 51.00)

 

11.7 (11.13, 12.95)

 

6.5 (5.55, 7.47)

 

cfEBV DNA copy number status

1.0^

 

0.3^

 

0.7^

 

0.5^

 

0.2^

 Positive

38.8 (31.88, 45.15)

 

27.7 (21.32, 35.30)

 

39.4 (29.90, 49.55)

 

11.7 (11.10, 12.69)

 

6.2 (5.51, 7.23)

 

 Negative

38.9 (31.07, 46.90)

 

31.7 (22.20, 39.90)

 

35.9 (26.70, 47.30)

 

11.6 (10.87, 13.18)

 

5.9 (4.89, 6.26)

 

 Not tested

40.4 (34.30, 43.25)

 

25.9 (18.80, 33.15)

 

36.2 (30.70, 50.45)

 

11.8 (11.17, 13.03)

 

6.7 (5.18, 7.09)

 

Treatment assigned

0.6

 

0.3

 

0.9

 

0.8

 

0.7

 Induction GCP + CRT

40.1 (31.67, 44.98)

 

26.4 (19.20, 33.92)

 

36.8 (29.90, 50.58)

 

11.8 (11.09, 12.95)

 

6.2 (5.36, 6.88)

 

 CRT only

38.6 (33.70, 44.95)

 

29.0 (21.40, 35.40)

 

36.9 (30.50, 48.65)

 

11.7 (11.08, 12.70)

 

6.1 (5.21, 7.46)

 

Sub-group analysis (n = 17)

Severe late xerostomiaa

0.2

 

0.5

 

0.2

 

0.08

 

0.05

 Control (n = 8)

34.8 (30.70, 38.97)

 

23.9 (20.63, 33.30)

 

35.6 (20.97, 45.55)

 

12.0 (10.79, 13.09)

 

6.2 (5.50, 7.32)

 

 Case (n = 9)

40.4 (33.47, 43.25)

 

26.3 (25.35, 33.15)

 

36.8 (34.90, 50.20)

 

11.1 (10.24, 11.35)

 

7.7 (6.57, 8.02)

 
  1. Reported values are median with corresponding interquartile range (25th percentile, 75th percentile)
  2. P-value calculated using Mann-Whitney U test. Highlighted in bold are values with significant p-values (p≤0.05)
  3. ^P-value calculated excluding the category: Not Tested
  4. aSub-group analysis based on a “Best case–control” design (See Additional file 1: Supplementary methods)
  5. Abbreviations: EBV Epstein-barr virus, GCP gemcitabine, carboplatin, paclitaxel, CRT chemo-radiotherapy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us